Literature DB >> 30231607

Neolignan Constituents with Potential Beneficial Effects in Prevention of Type 2 Diabetes from Viburnum fordiae Hance Fruits.

Chunchao Zhao1,2, Jia Chen1, Jianhua Shao1, Jie Shen1, Kehuan Li2, Wenyan Gu2, Sihui Li2, Judi Fan3.   

Abstract

Nine new neolignan glycosides (1-9), viburfordosides A-I, two new neolignans, fordianes A and B (10, 11), and seven known analogues (12-18) have been isolated and identified from the fruits of Viburnum fordiae Hance. The structures and absolute configurations of undescribed neolignan constituents were identified by chemical methods and spectroscopic analyses. The α-glucosidase inhibitory, ABTS•+ and DPPH• scavenging, and anti-inflammatory activities of these secondary metabolites were evaluated. Some of them exhibited significant potency in inhibiting α-glucosidase and scavenging free radicals. Among the 14 metabolites that were found to have the capacity to inhibit NO production in LPS-stimulated RAW264.7 macrophage cells, compounds 2, 4, 6, 10, 11, 14, 17, and 18 were potent with IC50 values of 10.88-41.10 μM. These results support that V. fordiae fruits possessing the neolignan compounds may serve as both a functional food and a medicinal resource to prevent and treat type 2 diabetes (T2D).

Entities:  

Keywords:  Adoxaceae; Viburnum fordiae Hance; anti-inflammatory; berry fruits; neolignans; radical scavenging; α-glucosidase inhibition

Mesh:

Substances:

Year:  2018        PMID: 30231607     DOI: 10.1021/acs.jafc.8b03772

Source DB:  PubMed          Journal:  J Agric Food Chem        ISSN: 0021-8561            Impact factor:   5.279


  1 in total

Review 1.  Genus Viburnum: Therapeutic Potentialities and Agro-Food-Pharma Applications.

Authors:  Javad Sharifi-Rad; Cristina Quispe; Cristian Valdés Vergara; Dusanka Kitic; Milica Kostic; Lorene Armstrong; Zabta Khan Shinwari; Ali Talha Khalil; Milka Brdar-Jokanović; Branka Ljevnaić-Mašić; Elena M Varoni; Marcello Iriti; Gerardo Leyva-Gómez; Jesús Herrera-Bravo; Luis A Salazar; William C Cho
Journal:  Oxid Med Cell Longev       Date:  2021-07-16       Impact factor: 6.543

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.